# US 2026/0027128 A1 · Orally inhaled and nasal benzodiazepines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0027128 A1
- Document ID: US20260027128A1
- Status: Published application
- Kind: A1
- Application number: 19/073,435
- Filed: 2025-03-07
- Published: 2026-01-29
- Earliest claimed: 2016-04-14
- Assignees: Paion UK Limited
- Applicants: Paion UK Limited
- Inventors: Karl-Uwe PETERSEN; Derek Jo SAKATA; Thomas STÕHR; John GRAHAM; Brett COOPER; Tatjana BEVANS; Christopher REILLY
- Web page: https://patentgrep.com/patent/US20260027128A1

## CPC

- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 9/0043: {Nose}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 23/00: Anaesthetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to Orally Inhaled and Nasal Drug Product (OINDP) comprising a benzodiazepine, in particular remimazolam.

## Claims

### Claim 1

A method for inducing or maintaining sedation, hypnosis, anxiolysis, anesthesia, muscle relaxation or treating convulsions in a patient, comprising administering to the patient by inhalation into lungs or sinuses of the patient a pharmaceutical composition comprising remifentanil and a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and one or more vehicles, carriers or excipients.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered to the patient by a device selected from a spray pump system, pipette for delivering drops, metered-dose spray pump, nasal pressurized metered-dose inhaler, powder spray system, breath-actuated powder inhaler, nasal powder insufflator, a metered dose inhaler, a dry powder inhaler and a nebulizer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound of formula (I) is a tosylate salt, a naphthalene-2-sulfonic acid salt, an esylate salt, or a besylate salt.

### Claim 4 (depends on 1)

The method of claim 1, wherein the concentration of remifentanil in the pharmaceutical composition is about 100 mcg/mL and the concentration of the compound of formula (I) in the pharmaceutical composition is about 25 mg/mL.

### Claim 5 (depends on 1)

The method of claim 1, wherein the concentration of remifentanil in the pharmaceutical composition is about 250 mcg/mL and the concentration of the compound of formula (I) in the pharmaceutical composition is about 10 mg/mL.

### Claim 6 (depends on 1)

The method of claim 1, wherein the concentration of remifentanil in the pharmaceutical composition is about 250 mcg/mL and the concentration of the compound of formula (I) in the pharmaceutical composition is about 25 mg/mL.

### Claim 7

An inhalation or intranasal drug delivery device comprising a pharmaceutical composition comprising remifentanil and a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and one or more vehicles, carriers or excipients.

### Claim 8 (depends on 7)

The device of claim 7, wherein the device is a spray pump system, pipette for delivering drops, metered-dose spray pump, nasal pressurized metered-dose inhaler, powder spray system, breath-actuated powder inhaler, nasal powder insufflator, a metered dose inhaler, a dry powder inhaler, or nebulizer.

### Claim 9 (depends on 7)

The device of claim 7, wherein the compound of formula (I) is a tosylate salt, a naphthalene-2-sulfonic acid salt, an esylate salt, or a besylate salt.

### Claim 10 (depends on 7)

The device of claim 7, wherein the concentration of remifentanil in the pharmaceutical composition is about 100 mcg/mL and the concentration of the compound of formula (I) in the pharmaceutical composition is about 25 mg/mL.

### Claim 11 (depends on 7)

The method of claim 7, wherein the concentration of remifentanil in the pharmaceutical composition is about 250 mcg/mL and the concentration of the compound of formula (I) in the pharmaceutical composition is about 10 mg/mL.

### Claim 12 (depends on 7)

The method of claim 7, wherein the concentration of remifentanil in the pharmaceutical composition is about 250 mcg/mL and the concentration of the compound of formula (I) in the pharmaceutical composition is about 25 mg/mL.
